Tim Brummendorf
Overview
Explore the profile of Tim Brummendorf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heuser C, Ernstmann N, Heier L, Nakata H, Geiser F, Karger A, et al.
Psychooncology
. 2024 Nov;
33(11):e70029.
PMID: 39562832
Objective: Children in families with parental cancer may experience emotional, social or physical problems. The aims are to analyze child, parent and family-based determinants of children's health-related quality of life...
2.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
3.
Mou Y, Lehmkuhl J, Sauerbrunn N, Kochel A, Panse J, Truh D, et al.
Stud Health Technol Inform
. 2024 Aug;
316:685-689.
PMID: 39176835
With cancer being a leading cause of death globally, epidemiological and clinical cancer registration is paramount for enhancing oncological care and facilitating scientific research. However, the heterogeneous landscape of medical...
4.
Loosen S, Van den Bosch V, Gorgulho J, Schulze-Hagen M, Kandler J, Jordens M, et al.
J Clin Med
. 2021 Apr;
10(7).
PMID: 33806224
Background: Immune checkpoint inhibitors (ICIs) represent a new therapeutic standard for an increasing number of tumor entities. Nevertheless, individual response and outcome to ICI is very heterogeneous, and the identification...
5.
Gresch G, Schenke L, Mladenov R, Zwirner S, Cremer C, Niesen J, et al.
Br J Haematol
. 2017 Oct;
183(2):313-317.
PMID: 29048126
No abstract available.
6.
Koch C, Reck K, Shao K, Lin Q, Joussen S, Ziegler P, et al.
Genome Res
. 2012 Oct;
23(2):248-59.
PMID: 23080539
Pluripotent stem cells evade replicative senescence, whereas other primary cells lose their proliferation and differentiation potential after a limited number of cell divisions, and this is accompanied by specific senescence-associated...
7.
Langer F, Steinmetz O, Marx G, Amirkhosravi A, Eifrig B, Bokemeyer C, et al.
Am J Hematol
. 2007 Aug;
82(12):1122-4.
PMID: 17665500
No abstract available.
8.
Lipton J, Khoroshko N, Golenkov A, Abdulkadyrov K, Nair K, Raghunadharao D, et al.
Leuk Lymphoma
. 2007 Apr;
48(3):497-505.
PMID: 17454589
The efficacy and safety of peginterferon-alpha-2a (40 kD) (PEG-IFNalpha-2a), 450 microg once weekly, versus IFNalpha-2a, 9 MIU once daily, for 12 months, was evaluated in a Phase II study in...
9.
Grunebach F, Mirakaj V, Mirakaj V, Muller M, Brummendorf T, Brossart P
Cancer Res
. 2006 Jun;
66(11):5892-900.
PMID: 16740729
In the present study, we analyzed the involvement of the BCR-ABL protein in the induction of antigen-specific CTL in order to develop an immunotherapeutic approach in patients with chronic myelogenous...
10.
Drummond M, Lennard A, Brummendorf T, Holyoake T
Leuk Lymphoma
. 2004 Jun;
45(9):1775-81.
PMID: 15223635
Chronic myeloid leukemia (CML) is associated increased stem cell turnover. We have previously shown that short telomeres in chronic phase (CP) predict for early progression to blast phase (BP). Poor...